RACGAP1 and invasive breast carcinoma: Overexpression of DCAF13, DNMT3B, KPNA2, EXO1, FANCI, RACGAP1, and ZNF106 in invasive breast carcinoma patients showed poor survival, while overexpression of CDKN2A, SORBS1, and TP63 showed better survival (Figures S4 and S5).